What question did this study set out to answer?

The aim was to analyze the incidence and severity of ocular and non-ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

May 29, 2026Journal of Clinical Oncology

Ocular toxicity and safety profile of mirvetuximab soravtansine in ovarian cancer: A systematic review and meta-analysis of clinical trials and real-world studies.

View Full Paper

Ask AI

Bookmark

The aim was to analyze the incidence and severity of ocular and non-ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.
Systematic review and meta-analysis following PRISMA guidelines.
Data from MEDLINE, PubMed, Embase, Scopus, and CENTRAL were analyzed, including both clinical trials and real-world studies.
Random-effects meta-analyses were performed to assess adverse events and their management.
Any-grade ocular adverse events occurred in 56.2% of clinical trial patients; grade ≥3 ocular events were rare at 1.41%.
Dose reductions due to ocular toxicity were noted in 31.2% of cases, while treatment discontinuation was less frequent at 9.98%.
Real-world studies showed a similar safety profile, with treatment discontinuation due to ocular events at just 0.35%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Systematic review assesses ocular and non-ocular adverse events in ovarian cancer testing mirvetuximab soravtansine, suggesting effective management strategies.

Cite This Study

Nagdev et al. (2026) studied this question.

synapsesocial.com/papers/6a192e39fab5b468c4417352 https://doi.org/10.1200/jco.2026.44.16_suppl.5558

View Full Paper

Ask AI

Bookmark

Implication

Systematic review assesses ocular and non-ocular adverse events in ovarian cancer testing mirvetuximab soravtansine, suggesting effective management strategies.

Ocular toxicity and safety profile of mirvetuximab soravtansine in ovarian cancer: A systematic review and meta-analysis of clinical trials and real-world studies.

Key Points

Discussion

Implication

Cite This Study

Ocular toxicity and safety profile of mirvetuximab soravtansine in ovarian cancer: A systematic review and meta-analysis of clinical trials and real-world studies.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider